Information

You are on the new improved site. You can view the old site in view-only mode here until June 27, 2026

loading
Phase 1 Trial of the Safety and Immunogenicity of PENNVAX ® -G DNA Prime Administered by Biojector ® 2000 or CELLECTRA ® EP Device with MVA-CMDR Boost